Infections with the paramyxoviruses, respiratory syncytial virus (RSV) and parainfluenza virus (PIV) can result in serious morbidity and mortality after haemopoietic stem cell transplant (HSCT). Once pneumonia develops, the outcome of these infections is often poor despite anti-viral therapy. Aerosolised ribavirin has been evaluated as pre-emptive therapy for post-transplant RSV infections with some success. Due to the financial and logistic burden involved with the use of aerosolised ribavirin, we explored the efficacy and toxicity of oral ribavirin for pre-emptive therapy of post-transplant RSV and PIV infections in a dose escalating schedule (15-60 mg/kg/day). Five episodes each of RSV and PIV were treated in seven patients. Five patients were receiving treatment for GVHD and two acquired the infection in the pre-engraftment period. All the episodes of RSV infection improved with oral ribavirin with dose escalation to 30-45 mg/kg in three of them. On the other hand, only two of the five PIV infections improved with oral ribavirin. Of the three non-responders, two infections were acquired in the pre-engraftment period with one death from PIV pneumonia. Reversible anaemia was the only side-effect noted in patients treated for over 2 weeks. Thus, the use of oral ribavirin was well tolerated in the post-transplant period with no untoward toxicities. There was a trend towards better response in RSV infections, which needs to be further explored in controlled studies. Bone Marrow Transplantation (2001) 28, 759-763.
Infections with the paramyxoviruses, respiratory syncytial virus (RSV) and parainfluenza virus (PIV) after haemopoietic stem cell transplant (HSCT) can result in significant morbidity and mortality. [1] [2] [3] [4] [5] RSV and PIV have been reported to account for most of the respiratory viral infections after transplant. [2] [3] [4] Progression to pneumonia occurs in about 50% of infected patients. [2] [3] [4] [5] Depending on the clinical setting, the mortality from pneumonia due to RSV and PIV varies between 30 and 100%.
Ribavirin is the only anti-viral drug in clinical use for the management of paramyxovirus infections. Aerosolised ribavirin is approved for use in RSV infections in high-risk children. However, ribavirin therapy has not improved the outcome of pneumonia due to these viruses in HSCT recipients. [1] [2] [3] [4] [5] Considering the poor prognosis of established paramyxovirus pneumonia, the emphasis has shifted to a preemptive approach with early initiation of treatment at the stage of upper respiratory tract (URI) infection or even at an asymptomatic stage. [6] [7] [8] [9] Small, uncontrolled studies suggest an improvement in the outcome of these infections with this pre-emptive approach. The difficulty in delivering aerosolised ribavirin, compounded by patient discomfort and the financial burden, makes widespread acceptance of this approach unlikely. 10 Moreover, in the absence of randomised studies, the clinical benefit from such an approach remains unsubstantiated.
The concept of pre-emptive therapy of post-transplant RSV or PIV infections would be more appealing if a less cumbersome and expensive approach were effective. Oral ribavirin is approved for use in hepatitis C infections. There is only one study reporting the use of oral ribavirin for respiratory virus infections after HSCT. 11 However, the efficacy and required oral dose of ribavirin in HSCT are uncertain.
Respiratory virus infections have been evaluated in our hospital over the last 3 years in an intensive surveillance programme. In a pilot study, we have prospectively explored the pre-emptive use of oral ribavirin, in a doseescalation schedule for early asymptomatic or mildly symptomatic paramyxovirus infections.
Patients and methods
A surveillance study for respiratory viruses was carried out in allograft recipients admitted to the BMT unit or attending the outpatient clinic of Birmingham Heartlands Hospital after December 1998. Patients were nursed in single rooms with laminar air-flow from the onset of conditioning treatment until engraftment. Conditioning treatments for allo-HSCT recipients were either conventional myeloablative regimens with or without TBI or nonmyeloablative regimens. The nonmyeloablative conditioning regimen consisted of fludarabine and melphalan combined with Campath 1-H in vivo 12 or in vitro. GVHD prophylaxis consisted of cyclosporin A.
All patients received anti-microbial prophylaxis with aciclovir, fluconazole, co-trimoxazole, metronidazole and ciprofloxacin. Patients at risk of cytomegalovirus (CMV) infection were pre-emptively treated if a qualitative PCR assay was positive.
Virology
All patients had weekly throat swabs for viral culture for the first 6 months after transplant. Patients with acute upper respiratory illness also had specimens obtained from nasopharyngeal aspirates (NPA) and sputum samples for virological investigation. Those with severe lower respiratory symptoms or respiratory failure underwent bronchoscopy and lavage. Chest radiography was performed in all symptomatic patients.
Nasopharyngeal aspirates, sputum and bronchoalveolar lavage (BAL) specimens were examined for PIV 3 by direct immunofluorescence and viral culture. The throat swabs were examined by culture only. Direct immunofluorescence (DIF) was carried out using fluorescein isothiocyanate-conjugated specific monoclonal antibodies (Dako Diagnostics, Ely, UK) for PIV 1, 2 and 3, influenza A and B, respiratory syncytial virus and adenovirus. Specimens for culture were inoculated into primary rhesus monkey kidney cells, primary liver carcinoma cells and MRC5 cell lines (Bio Whittaker, Wokingham, UK).
Treatment
All the patients infected with PIV 3 and RSV received ribavirin on an early initiation and dose escalation schedule, if they were within the first 100 days of an unmanipulated sibling transplant or 180 days of a T cell-depleted related or unrelated donor transplant or had acute/chronic GVHD. The aim of this pre-emptive approach was to prevent the progression to lower respiratory infections. Asymptomatic or mildly symptomatic ambulatory patients were treated with oral ribavirin (Rebetol; Schering-Plough Ltd, Welwyn Garden City, UK) at escalating doses. Treatment was commenced at 15 mg/kg and was increased by 15 mg/kg every week. The criterion for termination of treatment was virological response. The maximum dose used was 60 mg/kg. The patients were prescribed the nearest rounded dose of 200 mg capsules and were advised to take the drug with food. Any side-effects were noted on a weekly basis for 6 weeks after completion of therapy. Patients were advised to undertake contraceptive precautions for 6 months after cessation of ribavirin therapy. This was because the effect of nonmyeloablative regimens on fertility is unclear.
Patients with more severe symptoms were treated with aerosolised ribavirin (6 g/day in three divided doses for 5 to 7 days). Those patients with probable or definite LRI and those not responding to oral or aerosolised ribavirin were treated with intravenous (i.v.) ribavirin at 60 mg/kg daily in four divided doses for 5 to 10 days.
Definitions
Asymptomatic infection was defined as isolation of the virus on culture in the absence of clinical symptoms and signs. Upper respiratory illness (URI) was defined as the acute onset of any rhinorrhoea, sinusitis, pharyngitis or cough without clinical or radiological evidence of lower respiratory tract involvement and/or hypoxia and isolation of the virus from upper respiratory secretions. Lower respiratory illness (LRI) was defined as probable in the presence of clinical signs and symptoms of lower respiratory tract involvement with or without hypoxia, and definite when radiological evidence of new pulmonary infiltrates was present together with demonstration of the virus in BAL or lung tissues. Nosocomial infections were defined as infections acquired by patients after hospitalisation for at least 7 days.
Clinical response was defined as disappearance of respiratory symptoms and resolution of pyrexia and improvement of radiological abnormalities, if any. Virological response was defined as a negative result on direct immunofluorescence (DIF) and culture.
Anaemia due to ribavirin was defined as a drop in haemoglobin (Hb) level below 10 g/dl or a decrease in Hb concentration of у2 g/dl from a stable level over the previous 4 weeks without any other etiological factors. This was considered reversible if the Hb returned to the preexisting value within 4 weeks of stopping ribavirin.
Results
Ten episodes of paramyxovirus infections in seven patients were treated with oral ribavirin at a median of 244 days post transplant (range day 0 to day 556). Patient characteristics and outcome are summarised in Table 1 . Eight of the 10 episodes were associated with acute or chronic GVHD. Nine of these episodes occurred in six patients receiving nonmyeloablative conditioning. Five of them were conditioned with Campath in vivo.
RSV and PIV 3 accounted for five episodes each (Table  1) . Nine episodes were symptomatic. All five episodes of RSV infection improved with oral ribavirin. Three episodes required a dose escalation; two episodes to 30 mg/kg and one to 45 mg/kg. The other two episodes improved at the starting dose of 15 mg/kg. Three episodes were treated for 15 days, whereas the duration of therapy was 10-12 days in the other two episodes. None of the patients developed a definite LRI. All these patients had acute or chronic GVHD and were receiving steroids together with other immunosuppressants.
In contrast, PIV 3 infections required a longer duration of treatment with a higher dose. Two episodes improved promptly with oral ribavirin at 15 mg/kg in patient 1 who was on treatment for lung GVHD. Patient 3 acquired the infection during conditioning and was asymptomatic. 9 He did not respond to oral ribavirin at the highest dose or aerosolised ribavirin for 7 days. He subsequently had a virological response following i.v. ribavirin, which was started because of a probable LRI. Patient 4 had mild upper respiratory symptoms and was started on oral ribavirin but went on to develop probable LRI while on ribavirin 45 mg/kg. 9 He had a clinical response to i.v. ribavirin. However, he required a further course of oral ribavirin at 60 mg/kg before achieving a virological response. Patient 5, who acquired the virus during conditioning treatment, had mild to moderate upper respiratory symptoms. PIV 3 infection persisted despite clinical improvement with oral ribavirin at 60 mg/kg. She succumbed to progressive pneumonia soon after engraftment, despite treatment with i.v. ribavirin.
During the study period, protocol violation occurred in two unrelated donor transplants. A 49-year-old female with RSV infection during the pre-engraftment period was not treated pre-emptively at the discretion of the treating physician because of mild symptoms. Another 32-year-old male presented with interstitial pneumonia at 3 months post transplant. He did not report in for 2 weeks when he had mild upper respiratory symptoms. Both these patients succumbed to progressive pneumonia despite treatment with i.v. and aerosolised ribavirin and i.v. immunoglobulin
Oral ribavirin was very well tolerated to a dose up to 45 mg/kg. Two patients experienced moderate nausea at a dose of 45mg/kg and 60 mg/kg, respectively. Reversible anaemia was seen in all patients treated for 2 weeks or more. In patients 3 and 5 ribavirin could have been the cause of anaemia, but this cannot be stated with certainty as this was very early after the transplant.
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Discussion
Our study shows that oral ribavirin can be safely used in HSCT recipients at much higher doses than recommended for hepatitis C virus infection. The only consistent toxicity noted with prolonged use of the drug was reversible anaemia. This improved in all patients within 2 weeks of cessation of therapy. There was no gastro-intestinal intolerance except mild to moderate nausea in two patients.
There was an apparent difference in the pattern of response to ribavirin between RSV and PIV 3. While all the patients with RSV improved without any additional therapy, only two PIV 3 infections had similar improvement. However, there were other confounding factors which need consideration. Both the PIV 3 infections which did not improve with oral ribavirin occurred during conditioning therapy and persisted despite treatment with aerosolised ribavirin. Although they received nonmyeloablative conditioning, the oral absorption during the preengraftment period is likely to have been suboptimal. The patient who was categorised as a partial responder failed to achieve a virological response even with i.v. ribavirin. Thus, the poor response in these three patients is probably indicative of their different biological profile, rather than the effectiveness of oral ribavirin. Moreover, this was a pilot study of the feasibility of oral ribavirin in HSCT recipients and was not designed to answer the question about relative efficacy of the drug against RSV or PIV. However, there was clearly no relationship between severity of symptoms and duration of therapy as evident in patients 3 and 4. Both patients had mild or no symptoms at presentation and yet required the most protracted therapy with the addition of inhaled and iv ribavirin.
Infections occurring in patients with GVHD or in the pre-engraftment period constitute definite indications for treatment at most centres. 6 A notable feature in this cohort was the presence of significant GVHD and steroid therapy in the majority of patients. Patient 1 suffered from severe lung GVHD and was on potent immunosuppression including steroids. He had four episodes of RSV and PIV 3 infections, which were detected at an early stage. All four episodes improved with oral ribavirin only. The same pattern of improvement was also noted in other patients (patients 2, 6 and 7). Both the patients with RSV infection who were not treated pre-emptively during this study succumbed to RSV pneumonia.
We have previously suggested that severe CD4 ϩ lymphopenia following T cell-depleted transplants probably attenuates the inflammatory lung damage due to respiratory viruses. 13 The only death in the entire cohort was in a patient with mild GVHD not receiving a T cell-depleted graft or any additional immunosuppression. This adds further support to our hypothesis of the role of cellular immunity in the outcome of these infections.
Nebulised ribavirin has been used as early or pre-emptive therapy in several studies. 2, 3, [6] [7] [8] This involves hospital admission of fairly well patients and significant discomfort associated with prolonged periods of isolation and use of masks or tents. In addition, there is concern about healthrisks to the medical and nursing staff with environmental exposure to inhaled ribavirin. The cost of a 5-day course of aerosolised ribavirin is about $1300. A 15-day course of oral ribavirin can be administered at less than half that cost, also saving the additional burden of bed occupation and associated expenses.
Ribavirin administered orally is well absorbed but has a bioavailability of about 50% because of first-pass metabolism. 14 The wide volume of distribution is because of extensive cellular uptake via es-nucleoside transporters. Ribavirin is phosphorylated in the cells to the tri-phosphate, which is the active metabolite. To be released from the cells it needs to be de-phosphorylated which is a slow process accounting for a prolonged terminal half-life. This might produce a sustained antiviral effect even after cessation of therapy if treatment is for prolonged periods. The same pharmacokinetic mechanism might explain the invariable occurrence of anaemia with higher doses and prolonged therapy. Red cells, being anucleate, fail to de-phosphorylate the drug and have 60-fold concentration of the drug and an elimination half-life of 40 days. The release of ribavirin from red cells takes place by extravascular destruction. However, the anaemia was reversible in all cases and there was no delay in engraftment even with the use of the drug during the pre-engraftment period.
In animal models of liver disease, ribavirin has been shown to modulate the immune response by suppressing the Th2 response, thus shifting the balance in favour of Th1. 15 Whether such immunomodulation occurs in vivo is not known. Interestingly, we had noted a flare of GVHD in two patients receiving prolonged ribavirin therapy. While this could simply have been due to a reduction in the dose of steroids carried out at the same time, prolonged ribavirin therapy and the resultant Th1/ Th2 imbalance might have played a role. It is worth investigating the effect of ribavirin on cellular immunity in the clinical setting. This might be relevant in conjunction with further clarification of the role of Th1 and Th2 response in inflammatory lung damage associated with RSV or PIV3 infections. 16, 17 In conclusion, oral ribavirin can be safely used in posttransplant patients as pre-emptive therapy for RSV and PIV infections, with reversible anaemia being the only common complication. Our study suggests that such an approach might be beneficial, not too expensive and less cumbersome. Larger controlled studies are needed to address the role of oral ribavirin for paramyxovirus infections and further define the role of pre-emptive therapy of respiratory virus infections in HSCT recipients.
